SGEN Actualités Forex
Pfizer Closes $43 Bln All-cash Acquisition Of Seagen
Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
RTTNews
|
il y a 310
Pfizer Receives All Required Regulatory Approvals To Complete Seagen Acquisition
Pfizer Inc. (PFE) announced Tuesday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (SGEN).
RTTNews
|
il y a 312
Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints
Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).
RTTNews
|
il y a 393
Seagen Appoints David Epstein As New CEO
Biotechnology company Seagen Inc. (SGEN) announced Thursday that its Board of Directors has appointed David Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.
RTTNews
|
il y a 709
Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223
Seagen Inc. (SGEN), a pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (LVTX), a clinical-stage immuno-oncology company, announced Monday an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223.
RTTNews
|
il y a 754
